24/7 Market News Snapshot 13 March, 2025 – TransCode Therapeutics, Inc. Common Stock (NASDAQ:RNAZ)

March 13, 2025

DENVER, Colo., 13 March, 2025 (247marketnews.com) – (NASDAQ:RNAZ) are discussed in this article.
TransCode Therapeutics, Inc. is witnessing a remarkable upswing in its stock price, trading at $1.119, reflecting a substantial 9.71% increase from the previous close of $1.020 during pre-market hours. This surge has been bolstered by a robust trading volume of 2.98 million shares, indicating a heightened level of interest and engagement from investors. The positive momentum is likely fueled by recent encouraging developments concerning the company’s clinical initiatives, which could hint at an emerging trend among investors.

In a significant advancement, TransCode Therapeutics has received approval from its Safety Review Committee (SRC) to proceed with the fourth cohort of its ongoing Phase I clinical trial for TTX-MC138. This innovative oncology treatment, recognized as a first-in-class RNA therapeutic, specifically targets microRNA-10b, a biomarker associated with metastatic cancer. The SRC’s decision follows a thorough review of the safety outcomes from the previous cohort, allowing for a dose increase by approximately fifty percent.

The trial has already enrolled nine patients in the initial cohorts, with encouraging results showing that six participants have remained in the study without reporting major safety issues or dose-limiting toxicities. Notably, one patient has received up to seven doses over seven months, underscoring the treatment’s tolerability. Furthermore, the SRC has approved the enrollment of additional patients in Cohort 3, providing a deeper safety profile and facilitating the analysis of critical pharmacokinetic and pharmacodynamic data.

Sue Duggan, Senior Vice President of Operations, expressed enthusiasm regarding this pivotal development, emphasizing its importance in supporting future phases of the trial and the potential clinical efficacy of TTX-MC138. As the Phase I clinical trial progresses, TransCode is dedicated to advancing its mission of delivering innovative RNA therapeutic solutions to combat metastatic cancers.

Related news for (RNAZ)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.